Abstract：Objective To investigate the dynamic impact mechanism of different doses of Butylphthalide capsules on neural function recovery in patients with acute cerebral infarction. Methods This study included 120 patients with acute cerebral infarction admitted to our hospital's neurology department from January 2022 to January 2025.They were randomly assigned to a high-dose group(60 cases)and a low-dose group(60 cases)using a coin toss method.On the basis of conventional treatment,the high-dose group was given 200 mg of Butylphthalide soft capsules,while the low-dose group received 100 mg.The efficacy,hemorheological parameters,neurological function recovery,neuroregeneration factor levels,and adverse reactions were compared between the two groups. Results The clinical efficacy rate in the high-dose group(91.11%)was higher than that in the low-dose group(80.00%).After treatment,the erythrocyte aggregation index(2.32±0.44),whole blood viscosity(4.36±0.81 mPa.s),and plasma viscosity(1.44±0.42mPa.s)in the high-dose group were significantly lower than those in the low-dose group(P<0.05).The modified Rankin Scale(mRS)score in the high-dose group(1.98±0.68)was also significantly lower(P<0.05).Furthermore,the levels of brain-derived neurotrophic factor(BDNF)(3.50±1.28ng/L),nerve growth factor(NGF)(710.72±108.60ng/L),and gamma-aminobutyric acid(GABA)(4.26±0.74 μmol/L)in the high-dose group were significantly higher(P<0.05).Regarding adverse drug reactions,the incidence was 3.33% in the high-dose group,which was not statistically different from the low-dose group(P>0.05). Conclusion High-dose Butylphthalide capsules demonstrate better efficacy in treating acute cerebral infarction,significantly improving hemorheological parameters,promoting neurological function recovery,enhancing neuroregeneration-related factors,and showing a favorable safety profile.
2025, Vol. 45 
